Core Viewpoint - He Eye Hospital, a leading ophthalmology institution in Northeast China, is facing challenges due to management changes, underperformance of fundraising projects, and a significant decline in profits since its IPO in 2022 [1][2][3]. Group 1: Management Changes - In December 2025, the company experienced significant management changes, including the resignation of the general manager and the secretary of the board [8][9]. - The new general manager, He Xingru, is the son of the actual controllers, He Wei and He Xiangdong, indicating a continuation of family control [8][9]. Group 2: Financial Performance - He Eye Hospital's revenue for 2024 is projected to be 1.096 billion yuan, a decrease of 7.56% year-on-year, with a net loss of 27.3982 million yuan, a decline of 143.11% [2]. - The company reported a net profit of 54.3953 million yuan for the first three quarters of 2025, showing improvement compared to previous years, but the stock price continued to decline [8]. Group 3: Fundraising and Project Performance - The company raised approximately 1.296 billion yuan during its IPO, but many fundraising projects have not met expected returns or timelines [1][2]. - Specific projects, such as the Beijing and Chongqing new hospital projects, have incurred significant losses, with cumulative losses of 90.8468 million yuan and 69.5107 million yuan, respectively [3][6]. - The company has announced delays in project timelines, extending the expected operational status for several projects to 2026 and 2027 [5][6]. Group 4: Shareholder Actions - The fourth largest shareholder, Advanced Manufacturing Industry Investment Fund, plans to reduce its stake by up to 310,610 shares, representing 1.97% of the total shares [9][10]. - Previous reductions by the same fund have already occurred, indicating a trend of shareholder exits amid declining stock performance [10][12].
先进制造基金拟再度减持！何氏眼科管理层“换血”，董事长之子接任总经理，年薪85万元董秘辞职